JP Morgan Chase’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-33,900
Closed -$336K 7496
2024
Q2
$336K Hold
33,900
﹤0.01% 4891
2024
Q1
$399K Buy
+33,900
New +$434K ﹤0.01% 4945
2021
Q1
Sell
-257,500
Closed -$5.95M 6152
2020
Q4
$5.95M Buy
257,500
+27,500
+12% +$562K ﹤0.01% 2650
2020
Q3
$3.24M Buy
230,000
+68,900
+43% +$1M ﹤0.01% 2901
2020
Q2
$2.43M Buy
161,100
+140,000
+664% +$1.71M ﹤0.01% 2974
2020
Q1
$195K Sell
21,100
-18,900
-47% -$180K ﹤0.01% 4279
2019
Q4
$390K Buy
+40,000
New +$366K ﹤0.01% 4364
2019
Q3
Sell
-40,000
Closed -$480K 5803
2019
Q2
$480K Sell
40,000
-250,000
-86% -$3.17M ﹤0.01% 4263
2019
Q1
$3.94M Buy
+290,000
New +$3.54M ﹤0.01% 2786
2018
Q4
Sell
-550,000
Closed -$6.65M 5751
2018
Q3
$6.65M Buy
550,000
+310,000
+129% +$4.34M ﹤0.01% 2514
2018
Q2
$3.75M Buy
240,000
+150,000
+167% +$2.27M ﹤0.01% 2915
2018
Q1
$1.35M Sell
90,000
-10,000
-10% -$152K ﹤0.01% 3507
2017
Q4
$1.44M Buy
+100,000
New +$1.37M ﹤0.01% 3518
2017
Q3
Sell
-40,000
Closed -$403K 5028
2017
Q2
$403K Buy
+40,000
New +$322K ﹤0.01% 3806
2016
Q3
Sell
-70,000
Closed -$382K 4628
2016
Q2
$382K Buy
+70,000
New +$490K ﹤0.01% 3543

Other funds holding FOLD

JP Morgan Chase's FOLD Position: Q1 2026 in Review

JP Morgan Chase increased its Amicus Therapeutics (FOLD) stake by 82% in Q1 2026, buying an estimated $43.5M and bringing the position to 6,749,190 shares worth $97.4M. The position accounts for 0.01% of the portfolio, ranked #998.

JP Morgan Chase first reported a position in FOLD in Q2 2013 and has held it in 45 quarters since. The position peaked at $253M in Q4 2023. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • JP Morgan Chase held 6,749,190 shares of Amicus Therapeutics worth $97.4M as of Q1 2026.
  • JP Morgan Chase bought 3,031,827 Amicus Therapeutics shares in Q1 2026, an estimated $43.5M.
  • Amicus Therapeutics made up 0.01% of JP Morgan Chase's portfolio in Q1 2026, its #998 holding.
  • JP Morgan Chase first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 45 quarters since.
  • JP Morgan Chase's Amicus Therapeutics position peaked at $253M in Q4 2023.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.